AI Article Synopsis
Article Abstract
The definition of oligometastatic disease has evolved into distinct intermediate stages of different prognosis between single metastasis and polymetastatic disease. We assessed the therapeutic impact of such clinical definitions based on a review of the literature. Increasingly advanced stages of the metastatic disease with some prominent oligometastatic targets can be treated with stereotactic irradiation with ablative intent owing to its excellent tolerance profile. Used in different settings, metastatic ablation can either prolong progression free survival, delay change of systemic therapy or delay the time to symptoms. It may also improve survival, quality of life and health care costs in some situations. While most approaches have studied metastases by anatomic site rather than histology, combined systemic-ablative local treatment approaches are being developed for cancers of similar behavior. Biology-driven and imaging-oriented approaches are being investigated to better identify metastatic profiles for treatment guidance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2018.04.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Precision in Motion Management: Long-Term Local Control and Prognostic Insights in SBRT for Oligometastatic Lung and Liver Metastases.
Cancers (Basel)
January 2025
Department of Radiotherapy, Research Centre for Digital Medicine, VUB-UZ Brussel, 1090 Brussels, Belgium.
: Inadequate dosing and respiratory motion contribute to local recurrence for oligometastatic disease (OMD). While short-term LC rates are well-documented, data on long-term LC remain limited. This study investigated long-term LC after stereotactic body radiotherapy (SBRT), using respiratory motion management techniques.
View Article and Find Full Text PDFRadiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial.
BMC Cancer
January 2025
Department of Brachytherapy, Saint John's Cancer Center, Lublin, Poland.
Background: The current standard of care (SoC) for patients with extensive-disease small-cell lung cancer (ED-SCLC) is chemo-immunotherapy. The efficacy of radiotherapy (RT) for chest consolidation has been established for patients with ED-SCLC who have responded to chemotherapy. There is a lack of data on incorporating RT as chest consolidation and metastasis-directed therapy for ED-SCLC.
View Article and Find Full Text PDFMultimodal treatment improves survival in patients with lung metastases from colorectal cancer: A network meta-analysis.
Colorectal Dis
January 2025
Digestive Surgery and Liver Transplantation Unit, Archet 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France.
Aim: The lungs represent the second most common site of colorectal cancer metastases. Although surgery is commonly considered the best treatment, many other invasive and noninvasive procedures and treatments have been adopted to improve patient survival and there is no clear evidence in the literature of which is the more effective. The aim of this work was to identify which treatment confers the best gain in overall survival for patients with pulmonary metastases from colorectal cancer.
View Article and Find Full Text PDFEvolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma.
J Gastrointest Cancer
January 2025
Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Multiple randomized trials have suggested that the addition of comprehensive metastasis-directed therapy to best systemic therapy improves disease control and survival among patients with oligometastatic disease, even for histologies with a high propensity for rapid spread. Here, we review the growing literature supporting the oligometastatic paradigm in pancreatic ductal adenocarcinoma. We summarize key details from nascent institutional series and reflect on the recently reported phase II randomized EXTEND trial.
View Article and Find Full Text PDFReal-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.
ESMO Open
January 2025
Department of Woman's and Child health and Public Health Sciences, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Catholic University of the Sacred Heart, Rome, Italy. Electronic address:
Background: The utilization of poly-ADP-ribose polymerase (PARP) inhibitors (PARPi) as a first-line maintenance therapy for advanced ovarian cancer has increased significantly, with ∼80% of patients potentially eligible. This expansion has led to a rise in the population experiencing platinum-sensitive recurrence, yet data on first recurrence during PARPi are limited. This real-world study from a high-volume referral center aims to elucidate recurrence rates, disease distribution, and treatment modalities at the time of progression in PARPi-treated patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!